Abstract IA20: The NCI Cohort Consortium: Increasing power, enhancing collaborations, advancing science.

The Cohort Consortium is an extramural-intramural partnership formed by the National Cancer Institute (NCI) to foster communication among investigators leading cohort studies of cancer; promote collaborative research projects for topics not easily addressed in a single study; and identify common challenges in cohort research and search for solutions. The Cohort Consortium includes investigators responsible for more than 40 high-quality cancer epidemiology cohorts involving more than 4 million people. The cohorts are international in scope and cover large, rich, and diverse populations. Extensive risk factor data are available on each cohort, and biospecimens, including germline DNA collected at baseline, are available on more than 2 million individuals. Investigators team up to use common protocols and methods, and to conduct coordinated parallel and pooled analyses. Some recent accomplishments include publications of genome-wide association studies of pancreatic cancer and on the effect of high body mass index on mortality after eliminating the influence of tobacco smoking and co-morbidities. The Consortium provides a forum to discuss scientific questions in cancer research that cohort studies can help address such as how metabolomics can best be examined in human population studies and how cohort studies can better address the role of physical and chemical agents on cancer risk. It also can focus attention on new methodologies such as the use of social media and new ways of interacting with cohort study participants that could enhance data collection, data quality, and study participant retention and engagement.

Citation Format: Deborah M. Winn. The NCI Cohort Consortium: Increasing power, enhancing collaborations, advancing science. [abstract]. In: Proceedings of the AACR Special Conference on Post-GWAS Horizons in Molecular Epidemiology: Digging Deeper into the Environment; 2012 Nov 11-14; Hollywood, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2012;21(11 Suppl):Abstract nr IA20.